These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 20016365

  • 21. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer.
    Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI.
    Clin Genitourin Cancer; 2009 Oct; 7(3):E77-82. PubMed ID: 19815486
    [Abstract] [Full Text] [Related]

  • 22. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ, Sarao H.
    Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
    [Abstract] [Full Text] [Related]

  • 23. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.
    Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
    [Abstract] [Full Text] [Related]

  • 24. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP, Koutantos J, Vaslamatzis MM, Athanasiadis A, Papadopoulos G, Labrodimou G, Stathopoulos J, Rigatos S.
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [Abstract] [Full Text] [Related]

  • 25. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F.
    Cancer; 2001 Jun 01; 91(11):2039-45. PubMed ID: 11391583
    [Abstract] [Full Text] [Related]

  • 26. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 27. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
    Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarano R, Burrows W, Safran H.
    Am J Clin Oncol; 2012 Feb 20; 35(1):64-7. PubMed ID: 21297434
    [Abstract] [Full Text] [Related]

  • 28. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
    Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M.
    Urology; 2005 Mar 20; 65(3):543-8. PubMed ID: 15780373
    [Abstract] [Full Text] [Related]

  • 29. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J.
    J Clin Oncol; 2008 Nov 10; 26(32):5261-8. PubMed ID: 18794543
    [Abstract] [Full Text] [Related]

  • 30. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.
    Urology; 2005 Jan 10; 65(1):126-30. PubMed ID: 15667877
    [Abstract] [Full Text] [Related]

  • 31. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec 10; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 32. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
    Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H.
    Am J Clin Oncol; 2006 Aug 10; 29(4):376-9. PubMed ID: 16891865
    [Abstract] [Full Text] [Related]

  • 33. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov 10; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 34. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.
    BJU Int; 2010 Oct 10; 106(7):974-8. PubMed ID: 20230389
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P.
    BJU Int; 2007 Aug 10; 100(2):274-80. PubMed ID: 17355369
    [Abstract] [Full Text] [Related]

  • 39. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
    Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.
    J Clin Oncol; 2004 Jul 01; 22(13):2532-9. PubMed ID: 15226321
    [Abstract] [Full Text] [Related]

  • 40. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.